ImmunityBio

ImmunityBio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (T cell) immune system. We are developing molecular and product platforms including N-803, Aldoxorubicin, and a second-generation adenovirus vector, based upon our three key modalities of activating natural killer (‘NK’) and T cells, tumoricidal macrophages, and memory T cells. Please be aware of fraud or scams from individuals, organizations, and/or internet sites claiming to represent ImmunityBio in recruitment activities. We have an established recruitment process which is required for all posted positions by ImmunityBio prior to issuing an offer of employment. This ImmunityBio process requires formal interviews conducted live with personnel representing ImmunityBio and never requires payments or fees from job applicants. In the event that you receive a suspicious phone call, email or Linked InMail message about recruiting on behalf of ImmuntiyBio, unless it’s from an authorized recruiting associate, do not provide any personal information and never pay any fees. Qualified and interested candidates should apply to current openings directly through this ImmunityBio website. ImmunityBio accepts no responsibility for costs or charges incurred as a result of fraudulent activity.